Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Health Canada authorizes Moderna COVID-19 Vaccine in Canada.

Health Canada Authorizes Moderna COVID-19 Vaccine in Canada

Moderna (MRNA) shareholders have been hitting the exits at an aggressive pace in the last four weeks.

Moderna (MRNA) Down 30% After Posting All-Time High

Pfizer

Should You Worry About This Side Effect to Moderna's and Pfizer's COVID Vaccines?

Biogen

Bio-Rad Laboratories

CVS Health

Horizon Pharma

Insulet

QuidelOrtho Corp

Acceleron Pharma

Health Care Select Sector SPDR Fund

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Top Healthcare Stocks for January 2021

Chipotle

Dollar General

Pinduoduo Inc - ADR

SolarEdge Technologies

Tilray Brands

These hot stocks to buy by Jan. 1 have the potential to deliver short-term returns in addition to long-term gains throughout 2021. The post 7 Hot Stocks to Buy by Jan. 1 appeared first on InvestorPlace.

7 Hot Stocks to Buy by Jan. 1

BioNTech SE

Even with the relief brought by the conditional approval of two coronavirus vaccines, a more virulent and contagious variant of the virus in the U.K. has emerged.  Pfizer Inc. (NYSE: PFE), with its German partner BioNTech SE – ADR (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) are the two companies that have received approval for emergency use of their respective investigational vaccines.

Moderna, Pfizer Testing Coronavirus Vaccine Against New Strain

Even though Pfizer is the first-place finisher in the Covid-19 vaccine race, Moderna stock is worthwhile as there's room for two winners. The post With a Big Regulatory Win, Moderna Stock Is Worth Keeping appeared first on InvestorPlace.

With a Big Regulatory Win, Moderna Stock Is Worth Keeping

BioNTech's CEO said on Tuesday that while it is currently unclear whether the vaccine can protect against the new U.K. strain, it is “highly likely” the shot can protect against new variants.

Pfizer-BioNTech, Moderna Test Vaccines Against New Covid-19 Variant Spreading Across U.K.

The stock price of Moderna Inc (NASDAQ: MRNA) has received a price target of $180 by Brookline Capital Markets. These are the details.

Moderna Stock Price: $180 Target By Brookline

Moderna's Covid-19 vaccine received emergency approval from the U.S. FDA last week, with vaccinations likely to begin as soon as Monday. Initial shipments are likely to stand at about 6 million doses, with total shipments by the end of the month likely to rise to about 20 million.

What Investors Need To Know As Moderna's Vaccine Rolls Out

Moderna (MRNA) gets emergency use authorization for coronavirus vaccine, mRNA-1273, for use in adults in the United States.

Moderna (MRNA) Gets FDA Emergency Use Nod for COVID-19 Vaccine

Stocks Set to Confront the Virus in 2021 (NASDAQ: MRNA) (OTC: HALB) (NYSE: PFE)

The race to produce as much of the new vaccine as possible goes through these factories, which were spun up much faster than usual by building the shells before the vaccine production process was finalized. In a mountain valley in the Swiss Alps, new production lines are spinning up to produce the key ingredient for hundreds of millions of doses of Moderna's COVID-19 vaccine, which the Food and Drug Administration approved for emergency use in the U.S. on December 18.

Inside one of the new, quick-build factories making the Moderna vaccine

Novavax

Plug Power

Tesla

The world's largest cryptocurrency can't hold a candle to the returns of these high-flying stocks.

5 High-Growth Stocks That Crushed Bitcoin in 2020

McKesson

McKesson Corp., the giant health care distributor selected by the U.S. government to manage logistics for the COVID-19 vaccine immunization campaign, on Sunday began pushing out millions of doses of Moderna Inc.'s (NASDQ: MRNA) product in the back of FedEx and UPS trucks. On Monday, the express carriers will begin making deliveries to nearly 3,300 local dosing sites, and priority health care workers and residents of long-term care facilities will get vaccinated.

McKesson distribution centers ship first Moderna COVID-19 vaccines

IRVING, Texas--(BUSINESS WIRE)--McKesson Fills Initial Government Orders for Moderna's COVID-19 Vaccine

ADDING MULTIMEDIA McKesson Fills Initial Government Orders for Moderna's COVID-19 Vaccine

And it could be a long time before we know the answer.

$40 Billion Per Year for COVID Vaccine Makers Hinges on This 1 Unanswered Question

CAMBRIDGE, Mass.--(BUSINESS WIRE)--U.S. CDC Advisory Committee on Immunization Practices recommends vaccination with Moderna's COVID-19 Vaccine for persons 18 Years and older.

U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna's COVID-19 Vaccine for Persons 18 Years and Older

The U.S. Federal Aviation Administration on Saturday gave commercial pilots and air traffic controllers the green light to take Moderna Inc.'s (NASDQ: M R NA) COVID-19 vaccine, eliminating the possibility those who take the new drug might violate their medical certifications. The Food and Drug Administration on Friday approved Moderna's vaccine for public use on an emergency basis and the FAA quickly moved to endorse usage for two groups of essential transportation workers, as it did a week ago after Pfizer Inc.'s got the FDA's blessing.

FAA endorses Moderna COVID vaccine for pilots

The U.S. Federal Aviation Administration (FAA) said on Saturday it had approved the use of the Moderna COVID-19 vaccine by pilots and air traffic controllers.

U.S. FAA approves use of Moderna COVID-19 vaccine by pilots

A week after Pfizer Inc. (NYSE: PFE) received the greenlight for its vaccine against the coronavirus, the Food and Drug Administration cleared a similar vaccine candidate, mRNA-1273, from Moderna Inc (NASDAQ: MRNA). What Happened: The FDA authorized the emergency use of mRNA-1273 against COVID-19 in individuals 18 years and older, the Cambridge, Massachusetts-based biopharma said in a late Friday statement.

Moderna Finishes The Vaccine Race Close Behind Pfizer as FDA Authorizes Its Coronavirus Vaccine For Emergency Use

A second vaccine is available in the U.S.

Moderna Gains FDA Authorization for Its Coronavirus Vaccine

One week after authorizing the first COVID-19 vaccine for Americans, the Food and Drug Administration has granted a second emergency authorization, to Moderna Inc.'s COVID-19 vaccine.

FDA grants Moderna authorization for a second COVID-19 vaccine

Moderna's coronavirus vaccine has become the second to be approved for emergency use in the US.

Moderna coronavirus vaccine approved for emergency use in the US

This follows the authorization of Pfizer's coronavirus vaccine last week.

News for Moderna Stock (MRNA)